Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Moleculin, WPD ink licensing deal
April 2019
SHARING OPTIONS:

HOUSTON—In part to spur its preclinical and clinical development plans, Moleculin Biotech Inc. has begun a sublicense agreement with WPD Pharmaceuticals that grants the latter exclusive rights, subject to existing license agreements, to develop and market several of Moleculin’s technologies in specified European countries. In return, Moleculin will receive a minimum of $4 million in development expenditures agreed upon by Moleculin as well as an ongoing royalty on future revenues.
 
Walter Klemp, Moleculin’s chairman and CEO, said, “We estimate that the territories we are outlicensing represent approximately 10 percent of the worldwide spending on healthcare (as reported by the World Health Organization), and exclude key markets considered important to potential future outlicensing opportunities with ‘Big Pharma’ ... We believe this deal may allow us to pursue new indications for our lead drugs that otherwise would remain unexplored, which may ultimately increase our market opportunities and our chances for earlier drug approval. An added and extremely important benefit of this approach is that Moleculin doesn’t have to invest its own resources in establishing an EU-based infrastructure that would be required to access such grant funding of our own.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.